Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@ethio not sure if you've been in here before but @justhereforhemo put forward a good summary last week for potential investors (and also worth reading up / refreshing on for existing investors). We've also since then inked another agreement with Globalco for R&D for treatment of lupus and other autoimmune diseases - so the collaboration is hotting up.
https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Finance/gx-finance-next-generation-therapies.pdf - This has caused alot of excitement, largely page 8 where it details what other companies have been paid for licencing deals. Our CDX deal with Global Co feels around the 1-3billion mark if you look at similar technologies and target market. Also page 47 seems to imply Orgenesis have either acquired or attempting to acquire Hemogenyx-Cell SA. but this may just refer to the licencing deal...
Here are some comparisons: https://twitter.com/NiSpeach/status/1274411610187186178
Potential take over: https://t.co/wnpLlFj6Y4?amp=1 This got tweeted and retweeted by Vlad, nobody has said officially this is going to happen, just rumour and speculation, however they want to make acquisitions of 1-5bn small pharma with early stage cancer treatments. They are suspected also of being Global Co. If it happens and your a share holder when its announced...
https://twitter.com/justamantrading/status/1274378791511605249?s=20 Companies like J&J sharing our job advertisements
Zak Mir: https://zakmir.wordpress.com/2020/06/16/hemogenyx-hemo-more-than-a-covid-19-gold-rush-play-hemo/
https://www.v o x m a r k e t s.co.uk/articles/escape-hunt-vadim-alexander-of-novacyt-hemogenyx-alan-green-on-avacta-airtel-africa-team17-4c76120/ - 33mins 30secs in, if you have any remaining doubts.
Scart, BB - what's coming up here?
@bench that's a bit disconcerting :-0 lol
Im always watching Scart…. :-)
LOL you can tell new@this is new to this.
That old PI chestnut myth that if a director buys there can't be any news for the next month.
Disproved time and time again.
Do you need me to explain director buying rules?
@bench! Nice to see you on here :-)
Definitely great to see the FD topping up at these prices and shows confidence that the 5s are the bottom and hopefully moving up from here. Although I can't see that a ~£25k buy warranted the drop yesterday... anyways, onwards and upwards (I hope!)
new....we can still get a Covid update...
I think the timing of our Financial Controllers Buy tells us is
that a Deal with the Globalco is on the cards.......last
chance for Directors to buy...MM's played a blinder..again....
I am sorry for Newbies who they spooked yesterday.....
Morning all !!! The FD and his wife buying into the company !!!! FOLLOW THE MONEY !!!
I'm fine thanks, my average is lower than 5.6 and holding a few shares.
new@his if you know so much and cant apologise to peeps when they are right. What happened to your quote “Down to below 3p by next Friday” Waste of time listening to the noise that comes from this angle!!
He knows whats coming
Wonder if Andrew Wright had to get his buy in before July as Directors will
be entering a closed period due to deals being concluded in coming weeks???
Do you need me to explain Director buying rules!!
Mr wright purchased shares in January also ;
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has been advised that Andrew Wright, the Company’s Financial Controller and Company Secretary (PDMR), purchased 257,069 ordinary shares of £0.01 each in the Company (“Ordinary Shares”) at a price of 1.945p per share. Following this transaction, Mr Wright now has a total beneficial interest in 1,097,405 Ordinary Shares, representing approximately 0.28 per cent of the Company’s issued share capital as enlarged by the placing announced on 30 January 2020.
Ah Bless....new always pops in when good news lands.
last 7 sells are actually buys
Best you sell then.
6 v 1
NS Number : 5181R
Hemogenyx Pharmaceuticals PLC
30 June 2020
Hemogenyx Pharmaceuticals plc
(the "Company")
Director/PDMR Shareholding
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), and his wife, Olena Wright, have purchased a total of 434,704 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") at an average price of 5.76p per share. Following this transaction, Mr Wright has a total beneficial interest in 1,532,109 Ordinary Shares, representing approximately 0.35 per cent of the Company's issued share capital.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Andrew Wright...Our Financial Controller and his Wife
Was that the order MM's were filling.....Average price 5.76p
We are off................GLA!
Director and Wife buy 434,704 shares